Agent fee percentage Sale of Stock, Sales Agent Fee, Percentage Of Gross Proceeds Sale of Stock, Sales Agent Fee, Percentage Of Gross Proceeds Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Underwriters' option Over-Allotment Option [Member] Pay vs Performance Disclosure [Line Items] Statistical Measurement [Domain] Statistical Measurement [Domain] Credit facility, aggregate principal amount Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Related Party Transaction [Line Items] Related Party Transaction [Line Items] Interest income Interest Income, Other Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Outstanding, beginning balance (shares) Outstanding, ending balance (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Impairments of intangible assets Impairment of Intangible Assets (Excluding Goodwill) Credit Facility Agreement Debt Disclosure [Text Block] License agreement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Statement of Stockholders' Equity [Abstract] Credit Facility, Tranche Three Credit Facility, Tranche Three [Member] Credit Facility, Tranche Three Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Maximum milestone payments Collaborative Arrangement, Maximum Milestone Payment Collaborative Arrangement, Maximum Milestone Payment Proceeds from warrant cancellation payment Proceeds From Cancellation Of Warrants Proceeds From Cancellation Of Warrants MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restatement Determination Date: Restatement Determination Date [Axis] Corporate debt securities Corporate Debt Securities [Member] Other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Fair value, beginning of period Fair value, end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Total other income, net Nonoperating Income (Expense) Commitments and contingencies (Note 7) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Exercisable (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Proceeds from issuance of common stock, net of paid issuance costs Proceeds from Issuance of Common Stock Other non-current assets Increase (Decrease) in Other Noncurrent Assets Service condition period for full vesting Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Description of Business and Presentation of Financial Statements Business Description and Basis of Presentation [Text Block] Dividend yield rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 2016 Plan Equity Incentive Plan 2016 [Member] Equity Incentive Plan 2016 Concentration Risk [Line Items] Concentration Risk [Line Items] Director Director [Member] Leases Lessee, Leases [Policy Text Block] Revenue Recognition Revenue [Policy Text Block] Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Customer E Customer E [Member] Customer E Preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding Preferred Stock, Value, Issued Subsequent Event Type [Domain] Subsequent Event Type [Domain] Weighted Average Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Net loss per share, diluted (usd per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Intangible Assets, Net Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Line of Credit Line of Credit [Member] Beginning balance (shares) Ending balance (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Exercise of vested stock options Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-average grant-date fair value per stock option (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Net (loss) income Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Fair Value Disclosures [Abstract] Long-term investments: Equity Securities, FV-NI [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Non-cash lease expense Operating Lease, Noncash Expense Operating Lease, Noncash Expense LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Entity Ex Transition Period Entity Ex Transition Period Accretion of end of term charge Amortization of Debt Discount (Premium) Employee stock Employee Stock [Member] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Upfront payment Contract with Customer, Liability Exercise of vested stock options (shares) Exercised (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Net (loss) income per share, basis and diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of sales Cost of Goods and Services Sold Executive Category: Executive Category [Axis] Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Changes in fair value of equity warrants Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Summary of Significant Accounting Policies and Use of Estimates Significant Accounting Policies [Text Block] Exercised (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Marketable securities Marketable Securities, Current Name Forgone Recovery, Individual Name Issuance of pre-funded warrants, net of issuance costs of $0.6 million Adjustments to Additional Paid in Capital, Warrant Issued Property and equipment, net of accumulated depreciation Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Exercise price per warrant (usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Granted (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Smaller Reporting Company Entity Small Business Weighted average volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Laboratory equipment Other Machinery and Equipment [Member] Local Phone Number Local Phone Number Accounts receivable, net Increase (Decrease) in Accounts Receivable Unrealized gain from transactions denominated in a foreign currency Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Pharmakon Credit Facility, Tranche One Pharmakon Credit Facility, Tranche One [Member] Pharmakon Credit Facility, Tranche One Selling, general and administrative Selling, General and Administrative Expenses [Member] Customer B Customer B [Member] Customer B Accounts Receivable Accounts Receivable [Member] Stock options reserved for future grant (shares) Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant Milestone Determined by the Company Milestone Determined by the Company [Member] Milestone Determined by the Company Number of leases Lessee, Operating Lease, Number Of Lease Contracts Lessee, Operating Lease, Number Of Lease Contracts Operating lease liability, noncurrent Operating Lease, Liability, Noncurrent Restricted stock Restricted Stock Units (RSUs) [Member] Restricted stock unit activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Issuance costs Payments of Stock Issuance Costs Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation Depreciation Common stock in LianBio Common Stock In LianBio [Member] Common Stock In LianBio Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Income Statement Location [Axis] Income Statement Location [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Additional cash payment Revenue, Remaining Performance Obligation, Additional Cash Payment Revenue, Remaining Performance Obligation, Additional Cash Payment Future contractual lease payments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Stock issued (shares) Sale of Stock, Number of Shares Issued in Transaction Cost of Sales Cost of Goods and Service [Policy Text Block] Total revenues Revenues Number of vested warrants Number Of Vested Warrants Number Of Vested Warrants Financial instruments measured at fair value Fair Value, by Balance Sheet Grouping [Table Text Block] End of term charge, interest rate Line of Credit Facility, Periodic Payment, Interest Rate Line of Credit Facility, Periodic Payment, Interest Rate Outstanding potentially dilutive securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Accounts payable and accrued liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Total interest expense related to term loan Interest Expense, Debt 2023 ATM Prospectus 2023 ATM Prospectus [Member] 2023 ATM Prospectus Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Components of lease cost Lease, Cost [Table Text Block] Inventory Increase (Decrease) in Inventories Accounts payable and other accrued liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Research and development Research and Development Expense [Member] Cash Flows From Investing Activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Antidilutive securities excluded from computation of net income (loss) per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Granted (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Follow-On Public Offering Follow-On Public Offering [Member] Follow-On Public Offering Document Quarterly Report Document Quarterly Report Supplemental Disclosures Noncash Investing and Financing Activities: Noncash Investing and Financing Items [Abstract] Interest expense Interest Expense Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount License And Collaboration, Other License And Collaboration, Other [Member] License And Collaboration, Other Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Property and equipment, at cost Property, Plant and Equipment, Gross Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Operating lease right-of-use asset obtained in exchange for operating lease liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Unvested Share-Based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic Value Share-Based Compensation Arrangement By Share-based Payment Award, Options, Nonvested, Aggregate Intrinsic Value 2024 (remaining nine months) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Trading Arrangement: Trading Arrangement [Axis] Related Party Transactions Related Party Transactions Disclosure [Text Block] (Less): Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Summary of Interest Expense Interest Income and Interest Expense Disclosure [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Marketable securities: Debt Securities, Available-for-Sale [Abstract] Entity File Number Entity File Number End of term charge Line of Credit Facility, Periodic Payment, Interest Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Upfront payment received Collaborative Arrangement, Rights And Obligations, Upfront Payment Collaborative Arrangement, Rights And Obligations, Upfront Payment Operating lease liability, current Operating Lease, Liability, Current Pre-funded warrants reserved for future issuance (shares) Class of Warrant Or Right, Reserved for Future Issuance Class of Warrant Or Right, Reserved for Future Issuance Prepaid expenses Prepaid Expense, Current Net proceeds Proceeds from (Repayments of) Debt Pharmakon Credit Facility Pharmakon Credit Facility [Member] Pharmakon Credit Facility Customer C Customer C [Member] Customer C Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Long-term investments Long-Term Investments Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Total future amortization Finite-Lived Intangible Assets, Net Recently Issued or Effective Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Prepaid expenses Increase (Decrease) in Prepaid Expense Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Stock details Schedule of Stock by Class [Table Text Block] Cash and cash equivalents — beginning of period Cash and cash equivalents — end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Future cash payments Collaborative Arrangement, Future Cash Payments Collaborative Arrangement, Future Cash Payments Long-Lived Assets Held-for-Sale by Asset Type [Axis] Long-Lived Assets Held-for-Sale by Asset Type [Axis] Original issue price (usd per share) Sale of Stock, Price Per Share Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Variable lease expense Variable Lease, Cost Operating lease expense Operating Lease, Cost Common stock, issued (shares) Common Stock, Shares, Issued Vested (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Summary of estimated value of cash, cash equivalents, marketable securities, and equity securities Unrealized Gain (Loss) on Investments [Table Text Block] Valuation assumptions of stock options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Unvested (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Security Exchange Name Security Exchange Name Term loan, net Long-Term Debt Total assets measured at fair value Assets, Fair Value Disclosure Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Stock issued, net proceeds Sale of Stock, Consideration Received on Transaction Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Out-License Agreements Collaborative Arrangement Disclosure [Text Block] Stock options Stock options, unexercised—vested and unvested Employee Stock Option [Member] Unrecognized compensation expense, weighted average period of recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total operating expenses Costs and Expenses Maximum Maximum [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Unvested Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term Interest rate Line of Credit Facility, Interest Rate During Period Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Inventory Inventory, Policy [Policy Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Equity securities (in shares) Equity Securities, FV-NI, Number Of Shares Equity Securities, FV-NI, Number Of Shares Subsequent Event [Table] Subsequent Event [Table] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Tranches with minimum net sales milestones Debt Instrument, Number Of Tranches With Milestone Requirements Debt Instrument, Number Of Tranches With Milestone Requirements Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Unrealized losses Equity Securities, FV-NI, Unrealized Loss Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Subsequent Event Subsequent Event [Member] Customer Concentration Risk Customer Concentration Risk [Member] Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Issuance of common stock, net of issuance costs (shares) Stock Issued During Period, Shares, New Issues Forfeited (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Long-Lived Assets Held-for-Sale, Name [Domain] Long-Lived Assets Held-for-Sale, Name [Domain] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Five Customers Five Customers [Member] Five Customers Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Related Party [Domain] Related Party, Type [Domain] LianBio LianBio [Member] LianBio Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Outstanding, beginning balance (usd per share) Outstanding, ending balance (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Offering costs included within accounts payable and accrued liabilities Deferred Offering Costs Incurred But Not Yet Paid, Included In Accounts Payable And Accrued Liabilities Deferred Offering Costs Incurred But Not Yet Paid, Included In Accounts Payable And Accrued Liabilities Restricted stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Related party transaction, termination notice, period Related Part Transaction, Termination Notice, Period Related Part Transaction, Termination Notice, Period Inventory Inventory Inventory, Net Total lease expense Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Number of tranches Warrant Agreement, Number of Tranches Warrant Agreement, Number of Tranches Interest expense for term loan Interest Expense, Debt, Excluding Amortization Balance Sheet Location [Domain] Balance Sheet Location [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Total Shareholder Return Amount Total Shareholder Return Amount Product Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Accumulated amortization of debt issuance costs Accumulated Amortization, Debt Issuance Costs Number of securities with contractual maturity between one and five years Debt Securities, Available-for-Sale, Contractual Maturities Greater Than Twelve Months, Number of Securities Debt Securities, Available-for-Sale, Contractual Maturities Greater Than Twelve Months, Number of Securities Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Issuance of common stock upon the vesting of restricted stock units (shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Name Outstanding Recovery, Individual Name Interest rate floor Debt Instrument, Floor Interest Rate Debt Instrument, Floor Interest Rate Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Accounts payable and other accrued liabilities Accounts payable and other accrued liabilities Accounts Payable and Other Accrued Liabilities, Current Common stock in LianBio Estimated fair value Equity Securities, FV-NI Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Cash Flows From Operating Activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Unrealized (loss) gain on marketable securities and cash equivalents OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock, outstanding (shares) Beginning balance (shares) Ending balance (shares) Common Stock, Shares, Outstanding Proceeds from maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Earnings Per Share, Basic [Abstract] Earnings Per Share, Basic [Abstract] Grandpharma Grandpharma [Member] Grandpharma PEO PEO [Member] Concentration Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Bobak Azamian [Member] Bobak Azamian Cash Equivalents Cash Equivalents [Member] Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Customer [Domain] Customer [Domain] Inventories Schedule of Inventory, Current [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Debt Instrument [Axis] Debt Instrument [Axis] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Total operating lease liability Total operating lease liability Operating Lease, Liability Development and Regulatory Milestone Development And Regulatory Milestone [Member] Development And Regulatory Milestone Total liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Line of Credit, SVB Line of Credit, SVB [Member] Line of Credit, SVB Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Total shares of common stock reserved (shares) Common Stock, Capital Shares Reserved for Future Issuance All Executive Categories All Executive Categories [Member] Commercial and sales milestones Commercial And Sales Milestones [Member] Commercial And Sales Milestones Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Plan Name [Axis] Plan Name [Axis] Debt Disclosure [Abstract] Change in fair value of equity warrants issued by licensee Change in fair value of equity warrants issued by licensee Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Number of reportable segments Number of Reportable Segments Earnings Per Share [Abstract] Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Credit Facility, Tranche Four Credit Facility, Tranche Four [Member] Credit Facility, Tranche Four Marketable Securities and Long-Term Investments Marketable Securities, Policy [Policy Text Block] Common stock, $0.0001 par value; 200,000,000 shares authorized; 37,749,468 shares issued and outstanding at March 31, 2024 (unaudited); 34,211,190 shares issued and outstanding at December 31, 2023 Common Stock, Value, Issued Government-related debt securities US Government Debt Securities [Member] Selling, general and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Issuance costs, warrants Class of Warrant or Right, Payments of Issuance Costs Class of Warrant or Right, Payments of Issuance Costs Intangible Assets, Milestone Payment Intangible Assets, Milestone Payment [Member] Intangible Assets, Milestone Payment Weighted-Average Remaining Contractual Term Share-based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract] Share-based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Operating Segment Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current Common stock votes Common Stock, Number Of Votes Common Stock, Number Of Votes Product Sales from Each of our Largest Customers Schedules of Concentration of Risk, by Risk Factor [Table Text Block] All Individuals All Individuals [Member] Other income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Stock options issued and outstanding (shares) Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Related party transaction, annual cash compensation Related Party Transaction, Annual Cash Compensation Related Party Transaction, Annual Cash Compensation Net Loss per Share Earnings Per Share, Policy [Policy Text Block] Trade accounts payable and other Accounts Payable, Trade, Current PEO Name PEO Name Contractual maturity Debt Securities, Available-for-Sale, Term Concentration risk Concentration Risk, Percentage Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Preferred stock, authorized (shares) Preferred Stock, Shares Authorized Granted (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Expired (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Preferred stock, outstanding (shares) Preferred Stock, Shares Outstanding Accounts Receivable, Net Accounts Receivable [Policy Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Schedule of Expected Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Price per warrant (usd per share) Class of Warrant or Right, Sale Price Class of Warrant or Right, Sale Price Furniture and fixtures Furniture and Fixtures [Member] Interest rate Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Accrued payroll and benefits Increase (Decrease) in Employee Related Liabilities Statement of Financial Position [Abstract] Accrued clinical studies Accrued Clinical Studies, Current Accrued Clinical Studies, Current Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Commercial paper Commercial Paper [Member] Termination of equity warrants Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements Customer A Customer A [Member] Customer A Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Four Finite-Lived Intangible Asset, Expected Amortization, after Year Four Concentration Risk Type [Axis] Concentration Risk Type [Axis] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Subsequent Events [Abstract] Accrued product sales deductions Accrued Sales Commission, Current Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, issued (shares) Preferred Stock, Shares Issued Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Debt issuance costs Debt Issuance Costs, Line of Credit Arrangements, Net Preferred stock purchased Payments to Acquire Equity Securities, FV-NI Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Useful life Finite-Lived Intangible Asset, Useful Life Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Beginning balance (usd per share) Ending balance (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Pharmakon Credit Facility, Tranche Two Pharmakon Credit Facility, Tranche Two [Member] Pharmakon Credit Facility, Tranche Two Credit Facility, First Amendment, Tranche Two Credit Facility, First Amendment, Tranche Two [Member] Credit Facility, First Amendment, Tranche Two Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net Loss Per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Accretion of end of term charge Debt Instrument, Unamortized Discount (Premium), Net (Less): Tenant improvement allowance Lessee, Operating Lease, Liability, Tenant Improvement Allowance Lessee, Operating Lease, Liability, Tenant Improvement Allowance Document Fiscal Year Focus Document Fiscal Year Focus Minimum Minimum [Member] Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Stock option activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Unvested (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Special cash dividend (usd per share) Common Stock, Dividends, Per Share, Cash Paid Restricted stock units—unvested Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested [Member] Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Special cash dividends paid Dividends, Common Stock, Cash ASSETS Assets: Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Proceeds from term loan Proceeds from Issuance of Long-Term Debt License fees and Collaboration License And Collaboration [Member] License And Collaboration Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months [Member] Available-for-sale Debt Securities, Contractual Maturity Less Than 12 Months U.S. Treasury securities US Treasury Securities [Member] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Commitment & Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Number of available-for-sale debt securities in gross unrealized loss position for less than one year Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions Stock-based compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Net amortization/accretion on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities and stockholders’ equity Liabilities and Equity Credit Facility, Tranche Two Credit Facility, Tranche Two [Member] Credit Facility, Tranche Two Clinical milestones Clinical Milestones [Member] Clinical Milestones Amortized cost Amortized cost Debt Securities, Available-for-Sale, Amortized Cost Other income (expense): Nonoperating Income (Expense) [Abstract] Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Weighted average risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Net loss per share, basic (usd per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Sale of Stock [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] 2024 (remaining nine months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Shares issued in warrant conversion (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Related Party Related Party [Member] Customer D Customer D [Member] Customer D Days due within Termination Payment, Period Due Termination Payment, Period Due Balance Sheet Account Detail Supplemental Balance Sheet Disclosures [Text Block] Common stock issued for license agreement, value Stock Issued During Period, Value, Issued for Services Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Termination Date Trading Arrangement Termination Date Common stock, authorized (shares) Common Stock, Shares Authorized Corporate debt securities Debt Securities, Available-for-Sale Unrealized gains Equity Securities, FV-NI, Unrealized Gain Unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Principal outstanding Term loan, gross Long-Term Debt, Gross Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Elanco Elanco [Member] Elanco Compensation Amount Outstanding Recovery Compensation Amount Royalty expense Royalty Expense Additional paid-in capital Additional Paid in Capital Potential additional tranches Debt Instrument, Number Of Potential Additional Tranches Debt Instrument, Number Of Potential Additional Tranches Forfeited (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Subsequent Event Type [Axis] Subsequent Event Type [Axis] Authorized consideration Sale of Stock, Consideration Amount Authorized Sale of Stock, Consideration Amount Authorized Credit Facility, Tranche One Credit Facility, Tranche One [Member] Credit Facility, Tranche One Other receivables Increase (Decrease) in Other Receivables Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Forfeited (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Income Taxes Income Tax, Policy [Policy Text Block] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Forfeited (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Insider Trading Arrangements [Line Items] Upfront payment received Upfront Payment Upfront Payment Common stock issued for license agreement, share price (usd per share) Share Price Related Party [Axis] Related Party, Type [Axis] Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Milestone payments to be achieved Revenue, Remaining Performance Obligation, Variable Consideration, Amount Revenue, Remaining Performance Obligation, Variable Consideration, Amount Unrealized loss on equity investments Unrealized loss on equity investments Equity Securities, FV-NI, Unrealized Gain (Loss) Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of sales Cost of Sales [Member] Document Period End Date Document Period End Date Draw on credit facility Proceeds from Lines of Credit Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date (Less): Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Exercisable (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Entity Central Index Key Entity Central Index Key Accretion of term loan-related costs Amortization of Debt Issuance Costs and Discounts Remeasurement of equity warrants prior to termination Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Total stock-based compensation Share-Based Payment Arrangement, Expense 2023 Shelf Registration Statement 2023 Shelf Registration Statement [Member] 2023 Shelf Registration Statement Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Finished goods Inventory, Finished Goods, Net of Reserves Accrued payroll and benefits Employee-related Liabilities, Current Fair Value Measurements Fair Value Disclosures [Text Block] Number of operating segments Number of Operating Segments Revenue Benchmark Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Cash equivalents: Cash and Cash Equivalents [Abstract] Issuance of common stock, net of issuance costs of $6.7 million Stock Issued During Period, Value, New Issues Equity [Abstract] Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Pharmakon Credit Facility, Tranche Three Pharmakon Credit Facility, Tranche Three [Member] Pharmakon Credit Facility, Tranche Three Revenue recognized Revenue from Contract with Customer, Excluding Assessed Tax Other receivables Other Receivables, Net, Current Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Money market funds Money Market Funds [Member] Amortized cost Cash and Cash Equivalents, at Carrying Value Estimated incremental borrowing rate Operating Lease, Weighted Average Discount Rate, Percent Interest expense paid in cash Interest Paid, Excluding Capitalized Interest, Operating Activities Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Common stock issued for license agreement (shares) Stock Issued During Period, Shares, Issued for Services Useful lives of assets Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Term loan, net Long-Term Debt, Excluding Current Maturities Leasehold improvements Leasehold Improvements [Member] Selling, General and Administrative Selling, General and Administrative Expenses, Policy [Policy Text Block] Weighted-average shares outstanding, diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Cash and Cash Equivalents Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Contractual milestone payment Collaborative Arrangement, Rights And Obligations, Contractual Milestone Payment Collaborative Arrangement, Rights And Obligations, Contractual Milestone Payment Operating expenses: Operating Expenses [Abstract] Debt securities, available for sale and cash and cash equivalents Debt Securities, Available-For-Sale And Cash And Cash Equivalents Debt Securities, Available-For-Sale And Cash And Cash Equivalents Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional Paid-In Capital Additional Paid-in Capital [Member] Expired (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Cover [Abstract] Proceeds from issuance of pre-funded warrants, net of paid issuance costs Proceeds from Issuance of Warrants Subsequent Event Subsequent Events [Text Block] Recognition of stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amortization of debt issuance costs Amortization of Debt Issuance Costs Other long-term liabilities Other Liabilities, Noncurrent Vested (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Number of employment arrangements with executive officers Number Of Employment Arrangements With Executive Officers Number Of Employment Arrangements With Executive Officers Total future lease payments, undiscounted Lessee, Operating Lease, Liability, to be Paid Increments to draw on credit facility at company's election Line of Credit Facility, Draw Down Increments Line of Credit Facility, Draw Down Increments Prime Rate Prime Rate [Member] Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash Flows From Financing Activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Amortized cost Equity Securities, FV-NI, Cost Fair market value of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Work in process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted-average shares outstanding, basic (shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Loss from operations before other income (expense) Operating Income (Loss) Jose Trevejo [Member] Jose Trevejo Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Office equipment Office Equipment [Member] Revenues: Revenues [Abstract] Pharmakon Credit Facility, Tranche Four Pharmakon Credit Facility, Tranche Four [Member] Pharmakon Credit Facility, Tranche Four Proceeds from exercise of equity awards Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Concentration Risk [Table] Concentration Risk [Table] Property and Equipment, Net Property, Plant and Equipment, Policy [Policy Text Block] Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Equity warrants (for LianBio shares) Equity Warrants, Fair Value Disclosure Equity Warrants, Fair Value Disclosure Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Balances of Debt, Debt Issuance Costs, and Accumulated Accretion Schedule of Debt [Table Text Block] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table]